Limited evidence of pseudoprogression following immune checkpoint inhibitor (ICI) therapy in glioblastoma
John Y Rhee, Juan Pablo Ospina Botero, Thomas Nelson, Kun Wei Song, Michael W Parsons, Elizabeth R Gerstner, Jorg Dietrich
TL;DR
This study found little evidence of pseudoprogression in glioblastoma patients treated with immune checkpoint inhibitors.
Contribution
The study provides new insights into the rarity of pseudoprogression with ICI therapy in glioblastoma.
Findings
No pseudoprogression was observed in 55 glioblastoma patients treated with ICI.
Results were consistent across newly diagnosed and recurrent disease cases.
Abstract
“Pseudoprogression” following immune checkpoint inhibitors (ICI) in glioblastoma is often considered in case of radiographic progression. To better characterize the frequency of this phenomenon in glioblastoma, we reviewed the imaging response characteristics of a total of 55 patients treated with ICI in the setting of recurrent (n = 45) or newly diagnosed (n = 10) disease. There was no evidence of pseudoprogression related to ICI-monotherapy in the entire cohort.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsGlioma Diagnosis and Treatment · Cancer Immunotherapy and Biomarkers · Brain Metastases and Treatment